Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, the company announced. The lead Taiwan site is now open to accrual and actively screening patients, while Lantern anticipates IRB approval at two additional sites during the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation.
The approvals mark a significant step for Lantern’s biomarker-driven approach to drug development, which leverages its proprietary RADR artificial intelligence and machine-learning platform to identify patients most likely to benefit from its therapies. The HARMONIC trial is evaluating LP-300 in patients with the EGFR exon 21 L858R mutation who have progressed after tyrosine kinase inhibitor treatment. Part 2 will enroll these patients and allow LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously.
Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. The company cautions that these findings are preliminary, exploratory, and based on small patient numbers.
For investors and industry observers, the Taiwan approvals and the amended U.S. protocol signal progress in a niche area of oncology where targeted therapies are urgently needed. The L858R mutation is one of the most common EGFR mutations in non-small cell lung cancer, and patients who progress on tyrosine kinase inhibitors often have limited options. By extending LP-300 treatment to eight cycles, Lantern aims to deepen and prolong responses, potentially improving outcomes for this patient population.
Lantern’s RADR platform integrates large-scale genomic and biological data with advanced machine learning to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. This diversified pipeline and AI-driven approach position Lantern at the forefront of precision oncology, where the ability to match therapies to specific genetic alterations is increasingly critical.
The news is important for patients, clinicians, and investors because it demonstrates tangible progress in a trial that could lead to a new treatment option for a defined subset of lung cancer patients. If the HARMONIC trial continues to show promising results, LP-300 could become a valuable addition to the therapeutic arsenal for EGFR L858R-positive non-small cell lung cancer. For more details, the full press release is available at https://ibn.fm/CqeDR, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/LTRN.
Lantern Pharma is one of many companies covered by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides a range of services including wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer. For more information, visit www.BioMedWire.com.
